Arthritis drug JAK inhibitor Baricitinib treats baldness: patients get significant improvement

Lilly and Incyte have announced new data on the treatment of baldness by JAK inhibitor Baricitinib (OLUMIANT).
OLUMIANT is an oral JAK inhibitor that has been approved in the United States to treat adult patients with moderate to severe active rheumatoid arthritis who do not respond enough to one or more TNF inhibitors.
there are currently four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.
JAK has been found to be closely related to a variety of inflammatory and autoimmune diseases.
: Baldness is also an autoimmune disease that can cause unpredictable hair loss on the scalp, face and other parts of the body, and can occur at any age.
the ongoing Phase 2/3 BRAVE-AA1 study evaluated the safety and effectiveness of Baricitinib in adult bald patients.
interim analysis showed that in week 36, 33.3% of patients in the Baricitinib 2 mg dose group reached the primary endpoint of SALT≤20 (the hair loss rate was less than or equal to 20%), and 51.9% (p s 0.001) in the 4 mg dose group, and 3.6% in the placebo group.
, patients who received a dose of 4 mg of Baricitinib improved the growth of eyebrows and eyelashes (p .lt;0.05 compared to placebo).
most common adverse events are upper respiratory tract infections and no serious adverse events are reported.
Lotus Mallbris, vice president of immunology development at Lilly, said: "The results of this study highlight the potential of baricitinib in baldness, and we look forward to continuing baricitinib's clinical development program to become the first FDA-approved drug to treat baldness."
"Baricitinib's treatment effect on baldness (Photo:) In March, the FDA awarded Baricitinib breakthrough therapy based on a phase 2 positive result from BRAVE-AA1.